Water-based agent for thermal evaporation
Incorporating a glycol solvent with 4 to 6 carbon atoms in aqueous insecticide compositions addresses wick clogging and user discomfort, enhancing efficacy and stability for effective pest control.
Patent Information
- Application Number
- JP2020173232
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-10-14
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-10-14
AI Technical Summary
Aqueous insecticide compositions for heat evaporation face issues such as wick clogging, reduced pest control efficacy, and user discomfort due to solvent odor and irritation from glycol ether when heated.
Incorporating a glycol solvent with 4 to 6 carbon atoms at a concentration of 70 to 95 v/v% in the aqueous chemical, preferably with a 1,3-butylene glycol skeleton, to enhance solubility and stability, reducing solvent odor and irritation.
The solution increases the efficacy of active ingredients, improves usability by minimizing odor and irritation, and stabilizes the aqueous chemical system for effective pest control.
Smart Images

Figure 0007593770000005 
Figure 0007593770000006 
Figure 0007593770000001
Abstract
Description
[Technical field]
[0001] The present invention relates to an aqueous preparation for thermal evaporation, and more particularly to an aqueous preparation for thermal evaporation used in a thermal evaporation method in which an active ingredient absorbed in a thermal evaporation wick is evaporated by heating. [Background technology]
[0002] Conventionally, a liquid medicine for thermal evaporation is absorbed into a thermal evaporation wick, which is then heated to evaporate the active ingredient contained in the medicine for thermal evaporation, thereby obtaining the medicinal effect of the active ingredient.
[0003] As a heat-transfer agent, a heat-transfer insecticide composition containing a pyrethroid compound or the like as an active ingredient is widely used and various compositions are being studied. Since the active ingredients of pyrethroid compounds and the like are oil-based, most of them are formulated by dissolving them in an oil-based solvent such as kerosene.
[0004] On the other hand, for the purpose of achieving greater safety, aqueous insecticide compositions for thermal evaporation containing aqueous solvents such as water or glycol ether have been investigated. For example, Patent Document 1 proposes an aqueous insecticide composition for heat evaporation for controlling mosquitoes with reduced sensitivity to pyrethroid insecticidal components, the aqueous insecticide composition for heat evaporation containing 0.1 to 3.0 mass % of a pyrethroid insecticidal component, 10 to 70 mass % of at least one glycol ether compound having a boiling point of 150 to 300°C as an auxiliary agent for dealing with the reduced sensitivity, and water. [Prior art documents] [Patent documents]
[0005] [Patent Document 1] International Publication No. 2016 / 140172 Summary of the Invention [Problem to be solved by the invention]
[0006] However, the incorporation of an aqueous solvent into the insecticide composition for thermal evaporation can cause clogging of the thermal evaporation core and a decrease in the control effect against pests. In addition, glycol ether and the like have a strong solvent odor during thermal evaporation and are irritating, which can cause discomfort to users.
[0007] Therefore, an object of the present invention is to provide a new aqueous chemical for thermal evaporation that contains water and exhibits higher effects than conventional aqueous chemicals for thermal evaporation, while reducing the solvent odor and irritation during use. [Means for solving the problem]
[0008] The present inventors have conducted studies in light of the above problems and have found that the above problems can be solved by incorporating a glycol solvent having 4 to 6 carbon atoms in an aqueous pharmaceutical for thermal evaporation at 70 v / v % or more.
[0009] That is, the present invention is characterized by the following (1) and (2). (1) An aqueous preparation for thermal evaporation, comprising a thermally evaporable active ingredient, a glycol-based solvent having 4 to 6 carbon atoms, and water, the content of the glycol-based solvent being 70 to 95 v / v %. (2) The aqueous preparation for thermal evaporation according to (1) above, characterized in that the glycol-based solvent is a solvent having a 1,3-butylene glycol skeleton. Effect of the Invention
[0010] The aqueous preparation for thermal evaporation of the present invention can increase the efficacy of the active ingredient by thermal evaporation, and can reduce the solvent odor and irritation during use, improving the feeling of use. [Brief description of the drawings]
[0011] [Figure 1] FIG. 1 is a schematic diagram illustrating a test room used in an insecticidal efficacy test. [Diagram 2] FIG. 2 is a schematic diagram for explaining a test method for a sensory evaluation test. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] Hereinafter, the embodiments of the present invention will be described in more detail. The aqueous pharmaceutical preparation for thermal evaporation of the present invention contains a thermally evaporable active ingredient, a glycol-based solvent having 4 to 6 carbon atoms, and water.
[0013] The active ingredient is one that evaporates when heated, and can be appropriately selected depending on the application of the aqueous agent for thermal evaporation. Examples of the active ingredient include insecticides, repellents, bactericides / fungicides, deodorants / odor removers, and fragrances.
[0014] Examples of insecticides include pyrethroid compounds such as allethrin, phthalthrin, resmethrin, furamethrin, fenothrin, permethrin, empentrin, 1-ethynyl-2-ethyl-2-pentenyl-2,2,3,3-tetramethyl-cyclopropanecarboxylate, 1-ethynyl-2-methyl-2-pentenyl-2,2-dimethyl-3-(2',2'-dichlorovinyl)-cyclopropanecarboxylate, prallethrin, tefluthrin, transfluthrin, metofluthrin, and profluthrin; carbamethrin compounds such as propoxur and carbaryl; These include methionine compounds; organophosphorus compounds such as fenitrothion and diclofenac (DDVP); oxadiazole compounds such as methoxadiazone; phenylpyrazole compounds such as fipronil; sulfonamide compounds such as amidoflumet; hormone agents such as neonicotinoid compounds such as dinotefuran and imidacloprid, insect juvenile hormone agents such as methoprene and hydroprene, anti-juvenile hormone agents such as precocene, and molting hormone agents such as ecdysone; and essential oils such as fittoncides, peppermint oil, orange oil, cinnamon oil, benzyl alcohol, and clove oil.
[0015] Examples of repellents include DEET, paramenthan-3,8-diol, rotenone, di-n-butyl succinate, hydroxyanisole, ethyl 3-(Nn-butyl-N-acetylamino)propionate, and 1-piperidinecarboxylate 2-(2-hydroxyethyl)-1-methylpropyl ester.
[0016] Examples of bactericides and antifungal agents include isopropylmethylphenol, parachlorometaxylenol, triclosan, 3-iodomethyl-2-propenyl butylcarbamate, 2-(4-thiazolyl)benzimidazole, cetylpyridium chloride, 4-4-dimethyl-1,3-oxazolidine, poly(hexamethyl)biguanide hydrochloride, hinokitiol, and essential oils such as origanum oil, cinnamon oil, lemongrass oil, peppermint oil, and eucalyptus oil.
[0017] Examples of deodorants and deodorants include lauryl methacrylate, geranyl crotonate, catechin, polyphenols, and the like.
[0018] The fragrance may be either a natural fragrance or a synthetic fragrance, or may be a compound fragrance. The type of fragrance may be either an animal fragrance or a vegetable fragrance.
[0019] Examples of natural fragrances include animal fragrances such as musk, spirit cat fragrance, and dragon jasmine fragrance; rose oil, lavender oil, peppermint oil, lemon oil, abies oil, ajokun oil, almond oil, angelica root oil, peper oil, bergamot oil, perch oil, boa burdock oil, kayabuchi oil, gananga oil, capsicum oil, caraway oil, cardamom oil, cassia oil, celery oil, cinnamon oil, citronella oil, cognac oil, coriander oil, and thyme oil. Examples of plant-based flavorings include walnut oil, cupule oil, garlic oil, ginger oil, grapefruit oil, hops oil, juniper berry oil, laurel leaf oil, lemon oil, lemongrass oil, lopage oil, mace oil, nutmeg oil, mandarin oil, tangerine oil, mustard oil, lampflower oil, onion oil, pepper oil, orange oil, sage oil, star anise oil, turpentine oil, wormwood oil, and wanilla bean extract.
[0020] Examples of synthetic or blended fragrances include hydrocarbons such as pinene and limonene; alcohols such as linalool, geraniol, citronellol, menthol, borneol, benzyl alcohol, and anise alcohol; phenols such as anethole and eugenol; aldehydes such as n-butyraldehyde, isobutyraldehyde, citral, citronellal, benzaldehyde, cinnamic aldehyde, and vanillin; ketones such as carvone, menthone, and camphor; lactones or oxides such as amylbutyrolactone, ethyl methylphenylglycidate, γ-nonyl lactone, coumarin, and cineol; and esters such as isopropyl isobutyrate, guanyl isovalerate, ethyl myristate, ethyl benzoate, benzyl benzoate, cinnamyl cinnamate, and methyl salicylate.
[0021] The active ingredient may be used alone or in combination of two or more.
[0022] The active ingredient is preferably blended in an amount of 0.005 to 4.5 mL (v / v%) per 100 mL of the aqueous agent for thermal evaporation. If the content of the active ingredient is 0.005 v / v% or more, the effect of the active ingredient can be obtained, and if it is 4.5 v / v% or less, the system of the aqueous agent for thermal evaporation is stable. The content of the active ingredient is more preferably 0.01 to 3.0 v / v%, and even more preferably 0.05 to 1.5 v / v%.
[0023] In the present invention, the solvent contains at least water and a glycol-based solvent having 4 to 6 carbon atoms. Since the glycol-based solvent is amphipathic, it can dissolve the active ingredient, which is an oily ingredient, in the aqueous medicine for thermal evaporation, and also ensure safety during use. Furthermore, by using the glycol-based solvent having 4 to 6 carbon atoms, it is possible to reduce the solvent odor and irritation.
[0024] Examples of glycol-based solvents having 4 to 6 carbon atoms include 1,3-butylene glycol (carbon number: 4), 2,3-butylene glycol (carbon number: 4), diethylene glycol (carbon number: 4), isoprene glycol (carbon number: 5), 1,2-pentanediol (carbon number: 5), 1,3-pentanediol (carbon number: 5), 1,5-pentanediol (carbon number: 5), hexylene glycol (carbon number: 6), 1,6-hexanediol (carbon number: 6), 1,3-hexanediol (carbon number: 6), 1,2-hexanediol (carbon number: 6), dipropylene glycol (carbon number: 6), and triethylene glycol (carbon number: 6). Those having a boiling point in the range of 150 to 300° C. are preferred. The glycol solvent having 4 to 6 carbon atoms may be used alone or in combination of two or more. Among them, a glycol solvent having 4 to 6 carbon atoms and a 1,3-butylene glycol skeleton is preferred, and it is more preferred to use at least one selected from the group consisting of 1,3-butylene glycol, isoprene glycol, and hexylene glycol.
[0025] The glycol solvent having 4 to 6 carbon atoms is contained in the range of 70 to 95 mL (v / v%) in 100 mL of the aqueous pharmaceutical preparation for thermal evaporation. In the present invention, by using a large amount of the glycol solvent having 4 to 6 carbon atoms, the concentration of the thermally evaporable active ingredient contained in the evaporation particles becomes equal to or higher than the blending concentration in the aqueous pharmaceutical preparation for thermal evaporation, and it is presumed that the efficacy of the active ingredient can be increased. In addition, the unpleasant odor and irritation during thermal evaporation can be reduced, improving the feeling of use.
[0026] If the content of the glycol solvent having 4 to 6 carbon atoms is less than 70 v / v%, the solubility of the active ingredient decreases, the system of the aqueous drug for thermal evaporation becomes unstable, and long-term storage may become difficult. If the content of the glycol solvent having 4 to 6 carbon atoms is 70 to 95 v / v%, an effective amount of the active ingredient can be contained whether the active ingredient is oil-based or water-based, and the range of application of dissolving the active ingredient as a single liquid becomes wider regardless of the type of active ingredient. In addition, since the system of the aqueous drug for thermal evaporation can be stabilized, the content of the active ingredient that can be blended can be increased, and the active ingredient can be more effective than in conventional aqueous drug for thermal evaporation. The content of the glycol solvent having 4 to 6 carbon atoms is preferably 75 to 92 v / v %, more preferably 80 to 90 v / v %.
[0027] The water used can be that used for chemicals to be evaporated by heating, and examples of the water include distilled water, RO water, ion-exchanged water, and tap water.
[0028] The amount of water may be appropriately adjusted in consideration of the balance between the above-mentioned active ingredient and the content of the glycol solvent having 4 to 6 carbon atoms, the stability of the aqueous medicine for thermal evaporation, etc. The amount of water is preferably 0.5 to 29.9 mL (v / v%) in 100 mL of the aqueous medicine for thermal evaporation, more preferably 1.0 to 24.9 v / v%, and even more preferably 2.0 to 19.9 v / v%.
[0029] The aqueous medicine for thermal evaporation may contain other components within the range that does not impair the effects of the present invention. Examples of other components include organic solvents other than the above-mentioned glycol solvents having 4 to 6 carbon atoms, surfactants, stabilizers, dyes, etc.
[0030] Examples of organic solvents other than glycol-based solvents having 4 to 6 carbon atoms include aliphatic hydrocarbons (paraffinic hydrocarbons and unsaturated aliphatic hydrocarbons) having a boiling point range of 150 to 350°C, such as n-paraffin and isoparaffin, as well as alcohols such as glycerin, methanol, isopropanol, 1-octanol, and 1-dodecanol; ketones such as acetone and acetophenone; ethers such as dihexyl ether, diethylene glycol diethyl ether, and diethylene glycol monobutyl ether; esters such as dioctyl adipate, diethyl malonate, and diethyl phthalate; xylene, chlorthene, chloroform, and silicone oil. Among these, it is preferable to use an organic solvent having a boiling point in the range of 150 to 300°C.
[0031] Examples of the surfactant include polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan monooleate, and polyoxyethylene alkyl ether.
[0032] Examples of the stabilizer include 3,5-di-t-butyl-4-hydroxytoluene (BHT), 3-t-butyl-4-hydroxyanisole (BHA), 3,5-di-t-butyl-4-hydroxyanisole, mercaptobenzimidazole, dilauryl-thio-di-propionate, 2,2'-methylene-bis-(6-t-butyl-4-methylphenol), 2,2'-methylene-bis-(6-t-butyl-4-ethylphenol), 4,4'-methylene-bis-(2,6-di-t-butylphenol), 4,4'-butylidene-bis-(6-t-butyl-4-ethylphenol), butyl-3-methylphenol), 4,4'-thio-bis-(6-t-butyl-3-methylphenol), 1,1-bis-(4-hydroxyphenyl)cyclohexane, 1,3,5-trimethyl-2,4,6-tris(3,5-di-t-butyl-4-hydroxybenzyl)benzene, tris(2-methyl-4-hydroxy-5-t-butylphenyl)butane, tetrakis[methylene(3,5-di-t-butyl-4-hydroxyhydrocinnamate)]methane, octadecyl-3,5-di-t-butyl-4-hydroxyhydrocinnamate, and the like.
[0033] Examples of the dyes include Red No. 213 (Rhodamine B), Red No. 214 (Rhodamine B acetate), Red No. 215 (Rhodamine B stearate), Red No. 218 (Tetrachlorotetrabromofluorescein), Red No. 223 (Toluidine Red), Red No. 225 (Sudan III), Orange No. 201 (Dibromofluorescein), Orange No. 206 (Dioxyfluorescein), Yellow No. 204 (Quinoline Yellow SS), ), Green No. 202 (Quinizarin Green SS), Red No. 505 (Oil Red XO), Orange No. 401 (Hansa Orange), Orange No. 403 (Orange SS), Yellow No. 401 (Hansa Yellow), Yellow No. 402 (Pola Yellow 5G), Yellow No. 404 (Yellow AB), Yellow No. 405 (Yellow OB), Blue No. 403 (Sudan Blue B), Oil Blue BA, and Purple No. 201 (Arizulin Purple SS).
[0034] The aqueous formulation for thermal evaporation contains an active ingredient, an aqueous organic solvent having 4 to 6 carbon atoms, water, and optionally other ingredients, and can be prepared by mixing the ingredients uniformly, if necessary, with heating.
[0035] The aqueous medicine for thermal evaporation is preferably a liquid, since it is absorbed into a thermal evaporation wick for use. Note that "liquid" refers to a substance that is fluid and can change shape depending on the shape of the container.
[0036] In addition, since the aqueous chemical for thermal evaporation is used after evaporation by heating, it is preferable that the boiling point is within the range of 150°C to 300°C.
[0037] The thermal evaporation core used in thermal evaporation using the aqueous drug for thermal evaporation of the present invention is not particularly limited as long as it is practicable, and various inorganic and organic materials can be used. Usable materials include, for example, inorganic materials such as clay, talc, kaolin, acid clay, diatomaceous earth, activated clay, gypsum, perlite, bentonite, alumina, silica, titanium, asbestos, and ceramics, and organic materials such as wood flour, cellulose, pulp, polyester resin, acrylic resin, and other polymer resins. Among them, a synthetic fiber core made by solidifying at least one selected from polyester resin, acrylic resin, etc. in a fibrous form is preferable, and a porosity of 20 to 80% is more preferable.
[0038] The shape of the heating evaporation wick is not particularly limited, and examples thereof include a rectangular shape, a cylindrical shape, a rod shape, and the like.
[0039] The thermal evaporation using the aqueous chemical for thermal evaporation of the present invention can be carried out by a conventionally known method. Specifically, the thermal evaporation method can be carried out by attaching a thermal evaporation wick to a bottle filled with the aqueous chemical for thermal evaporation of the present invention, contacting the aqueous chemical for thermal evaporation with the thermal evaporation wick, setting the bottle in a thermal evaporation device, and heating the bottle by, for example, passing electricity through the bottle. The aqueous chemical for thermal evaporation that has been drawn up by the thermal evaporation wick is heated, causing the active ingredient to evaporate and be released into the air.
[0040] Regarding the heating conditions, if the heating temperature is too high, evaporation may occur too quickly and the heat-transpirable active ingredient may be prone to thermal decomposition, whereas if the heating temperature is too low, evaporation may occur too slowly and the effect of the heat-transpirable active ingredient may not be fully exerted. Therefore, heating at a temperature of 40 to 450°C is preferable, and 70 to 150°C is more preferable.
[0041] The present invention also provides a method for controlling pests using the aqueous formulation for thermal evaporation of the present invention. The aqueous formulation for thermal evaporation of the present invention, which contains an insecticide as an active ingredient, is heated to evaporate the active ingredient, thereby making it possible to control target pests.
[0042] The pests to be controlled are not limited as long as the effects of the present invention can be obtained, and examples thereof include flying pests such as mosquitoes, flies, moths, bees, stink bugs, weevils, beetles, powderpost beetles, burrs, and brown moths; crawling pests such as cockroaches such as the Smoky Brown cockroach, German cockroach, Japanese cockroach, American cockroach, and Brown cockroach, spiders, centipedes, ants, house centipedes, millipedes, pillbugs, woodlouse, termites, caterpillars, mites, lice, ticks, and bedbugs; and the like.
[0043] In order to ensure the effect of the present invention, the method for controlling pests using the aqueous agent for thermal evaporation of the present invention is preferably used in a closed space such as indoors or in a room. Specifically, a thermal evaporation wick is attached to a bottle filled with the aqueous agent for thermal evaporation of the present invention, and the bottle is set in a thermal evaporation device, which is then placed on an indoor floor or the like and electricity is applied to evaporate the insecticide into the indoor space, thereby controlling pests lurking in the room. EXAMPLES
[0044] The present invention will be further explained below with reference to the following test examples, but is not limited to these examples.
[0045] <Test Example 1: Insecticidal Efficacy Test> 1. Preparation of Test Specimens According to the formulations shown in Table 1, the components were mixed and stirred at room temperature to prepare drugs 1 to 7. In addition, as drug 8, "Water-based Kincho Liquid, odorless, replacement liquid" manufactured by Dainihon Jochugiku Co., Ltd. was prepared. It should be noted that drugs 1 and 2 are comparative examples, drugs 3 to 7 are working examples, and drug 8 is a reference example.
[0046] [Table 1]
[0047] 45 mL of each of the drugs 1 to 8 was filled into a 45 mL bottle for thermal evaporation, the bottle was closed, and a thermal evaporation wick (a wick taken from "Water-based Kincho Liquid, odorless, replacement liquid" manufactured by Dainihon Jochugiku Co., Ltd., dried so that no drug remained; made of ceramics) was inserted into the bottle to prepare test samples 1 to 8.
[0048] 2. Confirmation of insecticidal efficacy Test samples 1 to 8 were left to stand overnight in a thermostatic bath at 60° C. to allow the heat evaporation wick to absorb the drug and to equalize the liquid temperature of each sample, after which they were subjected to the following tests. The weight of each test sample was measured before and after the test, and the amount of evaporation of the aqueous pharmaceutical preparation for thermal evaporation was calculated by calculating the difference in weight.
[0049] (Test Method) (1) A PET cage (a 14-mesh, 23 cm x 23 cm PET net folded in half to form a bag) was prepared with approximately 20 Culex pipiens mosquitoes (adult females) in it as test insects. (2) As shown in Figure 1, a 6-tatami room (3.6m x 2.7m x 2.4m height ≒ 23.3m) 3 In the test room 10 of the test room 10, PET cages 1 containing Culex pipiens pallens were placed diagonally at heights of 0.75 m and 1.5 m from the floor of the test room 10, for a total of four cages. (3) The test specimen was placed in the heating evaporation device, which was then placed in the center 2 of the floor of the test chamber 10. With the test chamber 10 closed, electrical current was started. (4) The number of Culex pipiens mosquitoes knocked down in each test specimen was observed over time every 5 minutes for up to 2 hours after the start of the electric current. (5) The test was performed twice, and the knockdown rate was calculated from the total number of results obtained. The KT was calculated using the Probit method based on the knockdown rate over time. 50 The knockdown rate was calculated 30 minutes after the start of the current application. (6) The weight of the test specimen was measured, and the amount of evaporation was calculated from the weight before and after the test.
[0050] The results are shown in Table 2.
[0051] [Table 2]
[0052] Regarding the appearance of the prepared drugs, drugs 2 to 7 were solubilized and transparent, whereas drug 1 was cloudy, the emulsion was unstable, and separation was observed over time.
[0053] From the results in Table 2, test samples 3 to 7, which used drugs with a glycol solvent ratio of 70 v / v% or more (drugs 3 to 7), showed a good KT 50 The KT was less than 20 minutes, which was more effective than test samples 1 and 2. In addition, the higher the content of glycol-based solvent, the lower the amount of evaporation, but the higher the KT 50 It was found that the time was shortened, and in test samples 4 to 7, the knockdown rate after 30 minutes was 100%.
[0054] <Test Example 2: Sensory Evaluation Test> 1. Preparation of Test Specimens According to the formulation shown in Table 3, each component was stirred and mixed at room temperature to prepare drugs 9 to 12. Here, drugs 9 to 11 have the same formulation as drugs 4, 6, and 7 in Test Example 1, respectively. It should be noted that drugs 9 to 11 are examples, and drug 12 is a comparative example.
[0055] [Table 3]
[0056] 45 mL of each of the drugs 9 to 12 was filled into a 45 mL bottle for thermal evaporation, the bottle was closed with an inner stopper, and a thermal evaporation core (made of polyester fiber, core length 73.5 mm, core diameter 7.2 mm, porosity 62%) was inserted into the bottle to prepare test samples 9 to 12.
[0057] 2. Check the odor, irritation, and pleasantness / unpleasantness of the solvent Test samples 9 to 12 were left to stand overnight in a thermostatic chamber at 60° C. to allow the heat evaporation wick to absorb the drug and to equalize the liquid temperature of each sample, after which they were subjected to the following tests.
[0058] (Test Method) (1) As shown in FIG. 2, the heating and evaporation device 5 in which the test specimen was set was placed at a distance of about 2.19 m. 3 The device was placed in the center of the floor of a test chamber 20 (0.85 m x 1.35 m x 1.91 m high), and electricity was started with the test chamber 20 closed. (2) After 12 hours had passed since the start of the application of the current, the odor in the room was checked through the small window 6 of the test room 20, and the odor, irritation, and pleasantness / unpleasantness of the solvent were evaluated based on the following evaluation criteria. The evaluation was performed by 10 subjects, and the average evaluation score was calculated. [Evaluation of Solvent Odor] 1: I can smell it 2: Slightly smelly 3: Neither 4: I don't really notice any smell 5: No smell [Evaluation of Stimuli] 1: I feel stimulated 2: I feel some irritation 3: Neither 4: I don't feel much stimulation. 5: No irritation [Pleasure / displeasure level] 1: Unpleasant 2: Somewhat uncomfortable 3: Neither 4: Somewhat comfortable 5: Pleasure
[0059] The results are shown in Table 4.
[0060] [Table 4]
[0061] From the results in Table 4, it was found that test samples 9 to 11, which used a drug containing a glycol-based solvent, had higher ratings for the odor, irritation, and pleasantness of the solvent compared to test sample 12, which used a drug containing a glycol ether-based solvent, and were superior in usability. It should be noted that a solvent with an odor rating of 2 or higher, as well as an irritation rating and pleasantness rating, is deemed acceptable for use.
[0062] Test Examples 1 and 2 revealed that the aqueous formulation for thermal evaporation of the present invention not only has the inherent extermination effect, but also has an excellent feeling when mixed with water. It is presumed that it is possible to produce formulations that are effective not only for the above-mentioned insecticides, but also for deodorants and disinfectants, and that have a good feeling when used without irritation. [Explanation of symbols]
[0063] 1 PET cage containing Culex pipiens 2 Central part 5. Heating evaporation apparatus with test specimens set 6 Small Window 10,20 Test Room
Claims
1. The aqueous pharmaceutical for thermal evaporation, which is to be used by being absorbed into a thermal evaporation wick, comprises a thermally evaporable active ingredient, at least one glycol-based solvent selected from the group consisting of 1,3-butylene glycol, isoprene glycol, and hexylene glycol, and water, and is characterized in that the content of the glycol-based solvent is 80 to 95 v / v %.
2. A method for heat-evaporating an aqueous chemical for heat-evaporation, comprising: absorbing an aqueous chemical for heat-evaporation, the aqueous chemical for heat-evaporation containing a heat-evaporable active ingredient, at least one glycol solvent selected from the group consisting of 1,3-butylene glycol, isoprene glycol and hexylene glycol, and water, the glycol solvent content of which is 80 to 95 v / v %, into a heat-evaporation wick; and heating the aqueous chemical for heat-evaporation absorbed into the heat-evaporation wick to evaporate the active ingredient.
Citation Information
Patent Citations
Method of manufacturing water-based insecticide
JP2001131002A
Smoking type insecticide, smoking type insecticidal device, and insecticidal method
JP2012236813A
Heating-transpiration aqueous-insecticide composition and heating transpiration method of heating-transpiration aqueous-insecticide composition
WO2016140172A1
